PofoliaShared via Pofolia

Vascular Medicine· 2026Q2

Symptomatic primary aortic mural thrombus: Findings after 6 months of oral anticoagulation

Sarah-Jeanne Pardo, Guillaume Goudot, Francesca Pitocco, Andréanne Durivage et al.

Short summary

Six months of oral anticoagulation led to complete thrombus resolution in 17% and partial improvement in 48% of symptomatic primary aortic mural thrombus (PAMT) patients, with low recurrence (7%) and acceptable bleeding risk.

AI-generated from the title and abstract; the full text is not read.

Key points

  • Six months of oral anticoagulation achieved complete thrombus resolution in 17% and partial improvement in 48% of symptomatic PAMT patients.
  • 31% of thrombi remained stable, and 3% progressed after 6 months of anticoagulation.
  • Embolic recurrence occurred in 7% of patients, with one requiring thrombectomy.
  • Acceptable safety was demonstrated, with one major and three clinically relevant nonmajor bleeding events at extended follow-up.

AI-generated from the title and abstract; the full text is not read.

Abstract

BACKGROUND: Primary aortic mural thrombus (PAMT) is defined by an aortic thrombus in the absence of underlying aortic disease. Management relies on anticoagulation, with or without surgery, but optimal treatment duration remains uncertain. We evaluated clinical and radiological outcomes of symptomatic PAMT after 6 months of oral anticoagulation. METHODS: We performed a retrospective cohort study (2011-2022) reviewing all consecutive cases of aortic thrombosis. Inclusion criteria were symptomatic PAMT without prior anticoagulation. Patients treated surgically, without imaging follow-up, or lost to follow-up were excluded. Clinical, biological, and imaging data were collected. Radiological evolution was independently assessed by four physicians. RESULTS: Of 101 screened cases, 29 were included. Median age was 57 years (IQR 49-67), 66% were men, and cardiovascular risk factors were frequent (current and former smokers 86%, hypertension 55%, dyslipidemia 41%). Thrombi were mainly infrarenal (55%), followed by thoracic descending (21%), suprarenal abdominal (14%), and aortic arch (10%). Presentations included acute limb ischemia (76%) and organ infarction (21%). After a median of 180 days (IQR 167-208) of anticoagulation, thrombus evolution showed complete resolution in 17%, partial improvement in 48%, stability in 31%, and progression in 3%. Two embolic recurrences (7%) occurred, including one requiring thrombectomy. At extended follow-up (median 268 days), one major and three clinically relevant nonmajor bleeding events occurred; three deaths were unrelated to PAMT. CONCLUSIONS: Six months of anticoagulation in symptomatic PAMT achieves low recurrence and thrombus regression in most patients with acceptable safety. Prolonging anticoagulation beyond 6 months did not improve outcomes.

The authors' abstract, as published at the source. Vascular Medicine, 2026 · DOI ↗

TakeawaysPremium
Ask the paperFree account

Continue with a free account

Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.

Continue free on the web

Sign in with Google or Apple; no card needed. You come back to this paper.

On your phone:

Field: Pulmonary and Respiratory Medicine

Pulmonary and Respiratory MedicineMedicine